Going to BIO? Top 5 Things to Do While You’re in San Francisco
The BIO International Convention brings together more 15,000 biotechnology and pharma leaders for several days of intensive networking to discover new opportunities and promising p
A Bright Future for Pharma and Biotech in 2016
Before 2016 even officially kicked off, the life sciences industry received an early present to the tune of $32 billion. The House and Senate approved the 2016 spending bill, inclu
What You Cared About in 2015
As the year closes, one can’t help but reflect. So, we take a look back at our most popular blog posts from 2015. During the last 12 months, Chempetitive Group’s Chemunity blog
3-D Printing: Endless Possibilities for the Life Sciences
Although the technology has been around for decades, 3-D printing has in recent years gone mainstream––and all the possibilities it represents has the world at fever pitch. See
Surviving the J.P. Morgan Healthcare Conference [Plus Insider’s Guide]
Each January, the J.P. Morgan Healthcare Conference – perhaps the life science industry’s largest and most frenzied conference of the year – reliably draws thousands
Animal Biotechnology Part Two: Advances in the Veterinary Space
As we learned in part one of this series, the field of animal biotechnology consists of two main arms of research. Our focus today is the veterinary side. Unlike the agricultural s
Animal Biotechnology: The Business of Bovine
Pfizer, Johnson & Johnson, GlaxoSmithKline: Human drug developers are household names, but what about animal biotechnology – where does that fit in? We know it’s a science
One Giant Leap Too Far, Why CRISPR is in the News
The title reads: “Easy DNA Editing Will Remake the World. Buckle Up.” From the outset this article in July’s Wired magazine was in sensationalist territory. Nothing in scienc
Rare Diseases: The Role of Social Media in Patient Recruitment
Since the passing of the Orphan Drug Act in 1983, the rate of drug development in the United States has seen a significant increase. The act directly impacted funding – a maj
Want More Cures? Modernize Clinical Trials
As the federal government creates a plan to speed the pace of drug development in the U.S., one specialty contract research organization suggests that a more modernized approach to